Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RK-4 in acute large hemispheric infarction
NCT07166380Phase 2Not yet recruiting
- Sponsor
- NeuroDawn
- Start
- Sep 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in brain infarction, sponsored by NeuroDawn. Primary endpoints: Adverse Events at 14 days, Physical Examination Abnormalities at 14 days and 3 more. Planned start Sep 2025; status: not yet recruiting.
02
Conditions
brain infarction
Beyond the preview
Go deeper on NCT07166380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07166380.